Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of Stents Coated with Artemisinin or Dihydroartemisinin in a Porcine Coronary Restenosis Model

  • Jang, Suyoung (Korea Cardiovascular Stent Research Institute) ;
  • Jeong, Myung Ho (Korea Cardiovascular Stent Research Institute) ;
  • Lim, Kyung Seob (Cardiovascular Convergence Research Center Nominated by Korea Ministry of Health and Welfare) ;
  • Bae, In Ho (Korea Cardiovascular Stent Research Institute) ;
  • Park, Jun-Kyu (Cardiovascular Convergence Research Center Nominated by Korea Ministry of Health and Welfare) ;
  • Park, Dae Sung (Cardiovascular Convergence Research Center Nominated by Korea Ministry of Health and Welfare) ;
  • Shim, Jae Won (Cardiovascular Convergence Research Center Nominated by Korea Ministry of Health and Welfare) ;
  • Kim, Jung Ha (Cardiovascular Convergence Research Center Nominated by Korea Ministry of Health and Welfare) ;
  • Kim, Hyun Kuk (Cardiovascular Convergence Research Center Nominated by Korea Ministry of Health and Welfare) ;
  • Sim, Doo Sun (Cardiovascular Convergence Research Center Nominated by Korea Ministry of Health and Welfare) ;
  • Hong, Young Joon (Cardiovascular Convergence Research Center Nominated by Korea Ministry of Health and Welfare) ;
  • Ahn, Youngkeun (Cardiovascular Convergence Research Center Nominated by Korea Ministry of Health and Welfare) ;
  • Kang, Jung Chaee (Cardiovascular Convergence Research Center Nominated by Korea Ministry of Health and Welfare)
  • Received : 2016.07.22
  • Accepted : 2016.08.23
  • Published : 2017.01.31
⟨ Previous Next ⟩

Abstract

Background and objectives: Artemisinin and dihydroartemisinin are drugs used to treat malaria. These drugs suppress inflammatory reactions. The aim of this study was to examine the anti-intima hyperplasia effect of a novel drug-eluting stent with artemisinin or dihydroartemisinin in a porcine coronary restenosis model. Materials and Methods: Pigs were randomized into four groups; in the first, the coronary arteries (20 pigs, a total of 40 coronary arteries, with 10 coronary arteries in each group) was implanted with bare metal stents (BMS, n=10); the second group was given polymer-coated stents (PCS, n=10); the third group was treated with artemisinin-eluting stents (AES, n=10); and the fourth group was given dihydroartemisinin-eluting stents (DAES, n=10). Histopathologic analysis was performed 28 days after stenting. Results: The injury and fibrin scores among the four groups were not significantly different. However, the internal elastic lamina, lumen area, and neointima area were significantly different. Moreover, the percent area of stenosis ($46.2{\pm}18.66%$ in BMS vs. $89.4{\pm}10.92%$ in PCS vs. $83.3{\pm}17.07%$ in AES vs. $36.7{\pm}11.20%$ in DAES, p<0.0001) and inflammation score (1.0 [range: 1.0-1.0] vs. 3.0 [range: 2.25-3.0] vs. 3.0 [range: 1.0-3.0] vs. 2.0 [range: 1.75-3.0] in BMS, PCS, AES, and DAES, respectively; p<0.001) were markedly decreased in the DAES group compared to the PCS group. Conclusion: DES, which uses a natural substance, dihydroartemisinin, showed a neointima and inflammatory suppressive effect in a porcine coronary restenosis model.

Keywords

Acknowledgement

Supported by : Korean Society of Cardiology

References

  1. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501. https://doi.org/10.1056/NEJM199408253310802
  2. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloonexpandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489-95. https://doi.org/10.1056/NEJM199408253310801
  3. Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002;40:2082-9. https://doi.org/10.1016/S0735-1097(02)02597-4
  4. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network metaanalysis. Lancet 2007;370:937-48. https://doi.org/10.1016/S0140-6736(07)61444-5
  5. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimusand paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008. https://doi.org/10.1056/NEJMoa067193
  6. Bae IH, Lim KS, Park JK, et al. Mechanical behavior and in vivo properties of newly designed bare metal stent for enhanced flexibility. J Ind Eng Chem 2015;21:1295-300. https://doi.org/10.1016/j.jiec.2014.05.045
  7. Lim KS, Bae IH, Kim JH, et al. Mechanical and histopathological comparison between commercialized and newly designed coronary bare metal stents in a porcine coronary restenosis model. Chonnam Med J 2013;49:7-13. https://doi.org/10.4068/cmj.2013.49.1.7
  8. Ma X, Oyamada S, Gao F, et al. Paclitaxel/sirolimus combination coated drug-eluting stent: in vitro and in vivo drug release studies. J Pharm Biomed Anal 2011;54:807-11. https://doi.org/10.1016/j.jpba.2010.10.027
  9. Lim KS, Park JK, Jeong MH, et al. Biodegradable polymer-based sirolimus coating stent in a porcine coronary restenosis model. Clin Exp Thromb Hemost 2014;1:59-65. https://doi.org/10.14345/ceth.14015
  10. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992;19:267-74. https://doi.org/10.1016/0735-1097(92)90476-4
  11. Che HL, Bae IH, Lim KS, et al. Suppression of post-angioplasty restenosis with an Akt1 siRNA-embedded coronary stent in a rabbit model. Biomaterials 2012;33:8548-56. https://doi.org/10.1016/j.biomaterials.2012.07.045
  12. Schwartz RS, Edelman E, Virmani R, et al. Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation. Circ Cardiovasc Interv 2008;1:143-53. https://doi.org/10.1161/CIRCINTERVENTIONS.108.789974
  13. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-93. https://doi.org/10.1161/hc3601.093987
  14. Lim KS, Park JK, Jeong MH, et al. Comparison of sirolimus loaded PLGA-PEG co-polymer coronary stent and bare metal stent in a porcine coronary restenosis model. Macromol Res 2014;22:639-46. https://doi.org/10.1007/s13233-014-2095-9
  15. Kang SN, Kim SE, Choi J, et al. Comparison of phytoncide with sirolimus as a novel drug candidate for drug-eluting stent. Biomaterials 2015;44:1-10. https://doi.org/10.1016/j.biomaterials.2014.12.015
  16. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of instent restenosis: classification and implications for long-term outcome. Circulation 1999;100:1872-8. https://doi.org/10.1161/01.CIR.100.18.1872
  17. Sollott SJ, Cheng L, Pauly RR, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 1995;95:1869-76. https://doi.org/10.1172/JCI117867
  18. Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009;360:1946-59. https://doi.org/10.1056/NEJMoa0810116
  19. De Luca G, Dirksen MT, Kelbaek H, et al. Paclitaxel-eluting versus bare metal stents in primary PCI: a pooled patient-level meta-analysis of randomized trials. J Thromb Thrombolysis 2015;39:101-12. https://doi.org/10.1007/s11239-014-1091-4
  20. Cao Q, Jiang Y, Shi J, et al. Artemisinin inhibits tumour necrosis factor-alpha-induced vascular smooth muscle cell proliferation in vitro and attenuates balloon injury-induced neointima formation in rats. Clin Exp Pharmacol Physiol 2015;42:502-9. https://doi.org/10.1111/1440-1681.12375
  21. Cao Q, Jiang Y, Shi J, et al. Artemisinin inhibits the proliferation, migration, and inflammatory reaction induced by tumor necrosis factor-alpha in vascular smooth muscle cells through nuclear factor kappa B pathway. J Surg Res 2015;194:667-78. https://doi.org/10.1016/j.jss.2014.12.013
  22. Lee KP, Park ES, Kim DE, Park IS, Kim JT, Hong H. Artemisinin attenuates platelet-derived growth factor BB-induced migration of vascular smooth muscle cells. Nutr Res Pract 2014;8:521-5. https://doi.org/10.4162/nrp.2014.8.5.521
  23. Yang D, Yuan W, Lv C, et al. Dihydroartemisinin supresses inflammation and fibrosis in bleomycine-induced pulmonary fibrosis in rats. Int J Clin Exp Pathol 2015;8:1270-81.
  24. Yu WY, Kan WJ, Yu PX, Li MM, Song JS, Zhao F. Anti-inflammatory effect and mechanism of artemisinin and dihydroartemisinin. Zhongguo Zhong Yao Za Zhi 2012;37:2618-21.

Cited by

  1. Dihydroartemisinin ameliorates balloon injury‐induced neointimal formation in rats vol.234, pp.7, 2017, https://doi.org/10.1002/jcp.27809